Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke

Povzetek

Ključne besede

Podatki

Jezik:	Slovenski jezik
Leto izida:	2008
Tipologija:	1.04 - Strokovni članek
Organizacija:	OI - Onkološki inštitut Ljubljana
UDK:	616-006
COBISS:	620411
ISSN:	1408-1741
Matična publikacija:	Onkologija
Št. ogledov:	2213
Št. prenosov:	530
Ocena:	0 (0 glasov)
Metapodatki:

Ostali podatki

Sekundarni jezik:	Angleški jezik
Sekundarni naslov:	Update on Adjuvant Treatment of HER2-Positive Breast Cancer
Sekundarni povzetek:	Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer.
Sekundarne ključne besede:	Breast neoplasms;Drug therapy;Receptor, erbB-2;Antibodies, monoclonal;
URN:	URN:NBN:SI
Strani:	str. 57-60
Letnik:	ǂLetn. ǂ12
Zvezek:	ǂšt. ǂ1
Čas izdaje:	jun. 2008
ID:	10956197